Table 4.
Major epitope | This study (N = 18) | Previous studies (N = 15) | MAb* | ||
---|---|---|---|---|---|
Prevalence | Average frequency | Prevalence | Average frequency | ||
% (n) | % | % (n) | % | ||
DAHHAHHA | 100 (18) | 18 | 100 (15) | 18 | 3A4, PTL-3 |
DAHHAADAHH | 94 (17) | 8 | 100 (15) | 7 | 2G12-1C12 |
DAHHVADAHH | 0 (0) | 0 | 0 (0) | 0 | 2G12-1C12 |
YAHHAHHA | 94 (17) | 4 | 100 (15) | 4 | 1E1-A9, PTL-3 |
DAHHAHHV | 89 (16) | 5 | 100 (15) | 3 | 1E1-A9 |
HATDAHHAAD | 61 (11) | 2 | 67 (10) | 3 | A6-4 |
HATDAHHAAA | 67 (12) | 2 | 100 (15) | 2 | A6-4 |
AHHAADAHHA | 100 (18) | 26 | 100 (15) | 26 | C1-13 |
DAHHAADAHHA | 94 (17) | 8 | 100 (15) | 7 | N7 |
AHHAADAHH | 100 (18) | 26 | 100 (15) | 26 | S2-5, C2-3 |
AHHASDAHH | 78 (14) | 2 | 100 (15) | 2 | S2-5 |
TDAHHAADAHHAADA | 50 (9) | 1 | 53 (8) | 1 | TC-10 |
AAYAHHAHHAAY | 0 (0) | 0 | 0 (0) | 0 | Genway |
MAb = monoclonal antibody; pfhrp2 = Plasmodium falciparum histidine-rich protein 2 gene.
Lee et al.18